Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findings.

ABSTRACT:

Background

Glioblastoma (GBM) is the most aggressive primary brain malignancy with <45% living a year beyond diagnosis. Previously published investigations of long-term survivors (LTS) provided clinical data but rarely incorporated a comprehensive clinical and molecular analysis. Herein, we identify clinical, imaging, molecular, and outcome features for 23 GBM-LTS patients and compare them with a matched cohort of short-term survivors (STS).

Methods

Molecularly confirmed Isocitrate Dehydrogenase (IDH) wildtype GBM patients living ≥3 years post-diagnosis (N_LTS = 23) or <3 years (N_STS = 75) were identified from our Natural History study. Clinical and demographic characteristics were compared. Tumor tissue was analyzed with targeted ne

SUBMITTER: Briceno N 

PROVIDER: S-EPMC10901543 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature